Results 181 to 190 of about 202,276 (321)

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

British Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian, Chiara Arrigoni, Francesco Bertoni, Matteo Moretti   +12 more
wiley   +1 more source

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [PDF]

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang   +13 more
openalex   +1 more source

Rarity to Remission: Complete Response of Primary Breast Diffuse Large B-Cell Lymphoma With Chemoimmunotherapy. [PDF]

Clin Case Rep
Jha A, Ghosh V, Gupta S, Oli S, Rayamajhi A, Gupta D, Luitel A, Khanal B, Dahal A, Khadka S.   +9 more
europepmc   +1 more source

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

British Journal of Haematology, EarlyView.
Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland   +9 more
wiley   +1 more source

The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma. [PDF]

Noncoding RNA
Panteli E, Koumpis E, Georgoulis V, Barakos GP, Kolettas E, Kanavaros P, Papoudou-Bai A, Hatzimichael E.   +7 more
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma Patient with later Exuberant Plasmablastic Lymphoma

, 2015
Carolina Marini Marta Gomes, Fernanda Trigo   +1 more
openalex   +1 more source

Clinical features and incidence of central nervous system involvement in patients with adult T‐cell leukaemia/lymphoma

British Journal of Haematology, EarlyView.
Summary Central nervous system (CNS) involvement is a known complication of adult T‐cell leukaemia/lymphoma (ATL), but its clinical characteristics and incidence still remain unclear. This study characterized the clinical features and incidence of CNS involvement in patients with ATL (CNS‐ATL).
Takuya Ueno, Makoto Yoshimitsu, Momone Sameshima, Taichi Nagano, Rika Akahoshi, Yusetsu Takeshita, Aya Shodai, Kodai Shima, Naosuke Arima, Yuhei Kamada, Daisuke Nakamura, Kenji Ishitsuka   +11 more
wiley   +1 more source

When the Heart Is the Target: Case of Primary Pericardial Diffuse Large B-Cell Lymphoma Presenting With Tamponade. [PDF]

Case Rep Oncol Med
Bawwab A, Khatib L, Albliwi MAS, Yang L, Zhao PJ.   +4 more
europepmc   +1 more source

Case report: Diffuse large B cells lymphoma in the cervix

, 2017
Rodolfo Mendes Queiroz, Gustavo C. Melges, Juliane A. Paron, Paulo Roberto Félix, Glaucia A. Magnani Landell, Eduardo M. Febronio, Márcio Castro e Silva   +6 more
openalex   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source